Evidence map›Paper›PMID 32612161›Full record

ArticleScientific reports2020

Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.

María T Berciano, Alba Puente-Bedia, Almudena Medina-Samamé, José C Rodríguez-Rey, Jordi Calderó, Miguel Lafarga, Olga Tapia

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Principles and functions of condensate modifying drugs.Frontiers in molecular biosciences · 2022
    Review
  15. Review
  16. Article
  17. Article
  18. Pseudogenes in Cardiovascular Disease.Frontiers in molecular biosciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

María T Berciano *Department of Molecular Biology, University of Cantabria, Santander, Spain.
Alba Puente-Bedia *Department of Physiology and Pharmacology, University of Cantabria, Santander, Spain.
Almudena Medina-SamaméDepartment of Anatomy and Cell Biology, University of Cantabria, Santander, Spain.
José C Rodríguez-ReyDepartment of Molecular Biology, University of Cantabria, Santander, Spain.
Jordi CalderóDepartment of Experimental Medicine and "Institut de Recerca Biomèdica de Lleida" (IRBLleida), University of Lleida, Lleida, Spain.
Miguel LafargaDepartment of Anatomy and Cell Biology, University of Cantabria, Santander, Spain.
Olga Tapia"Instituto de Investigación Marqués de Valdecilla" (IDIVAL), Santander, Spain. otapia@idival.org.
Instituto de Investigación Marqués de Valdecilla · ESUniversidad de Cantabria · ESBiomedical Research Institute of Lleida · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spinal muscular atrophy (SMA) is a devastating autosomal recessive neuromuscular disease characterized by degeneration of spinal cord alpha motor neurons (αMNs). SMA is caused by the homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene, resulting in reduced expression of SMN protein, which leads to αMN degeneration and muscle atrophy. The majority of transcripts of a second gene (SMN2) generate an alternative spliced isoform that lacks exon 7 and produces a truncated nonfunctional form of SMN. A major function of SMN is the biogenesis of spliceosomal snRNPs, which are essential components of the pre-mRNA splicing machinery, the spliceosome. In recent years, new potential therapies have been developed to increase SMN levels, including treatment with antisense oligonucleotides (ASOs). The ASO-nusinersen (Spinraza) promotes the inclusion of exon 7 in SMN2 transcripts and notably enhances the production of full-length SMN in mouse models of SMA. In this work, we used the intracerebroventricular injection of nusinersen in the SMN∆7 mouse model of SMA to evaluate the effects of this ASO on the behavior of Cajal bodies (CBs), nuclear structures involved in spliceosomal snRNP biogenesis, and the cellular distribution of polyadenylated mRNAs in αMNs. The administration of nusinersen at postnatal day (P) 1 normalized SMN expression in the spinal cord but not in skeletal muscle, rescued the growth curve and improved motor behavior at P12 (late symptomatic stage). Importantly, this ASO recovered the number of canonical CBs in MNs, significantly reduced the abnormal accumulation of polyadenylated RNAs in nuclear granules, and normalized the expression of the pre-mRNAs encoding chondrolectin and choline acetyltransferase, two key factors for αMN homeostasis. We propose that the splicing modulatory function of nusinersen in SMA αMN is mediated by the rescue of CB biogenesis, resulting in enhanced polyadenylated pre-mRNA transcription and splicing and nuclear export of mature mRNAs for translation. Our results support that the selective restoration of SMN expression in the spinal cord has a beneficial impact not only on αMNs but also on skeletal myofibers. However, the rescue of SMN expression in muscle appears to be necessary for the complete recovery of motor function.

Indexed as

Disease Models, AnimalActive Transport, Cell NucleusAnimalsCoiled BodiesMiceMice, KnockoutMotor NeuronsMuscular Atrophy, SpinalOligonucleotidesRNA, MessengerSurvival of Motor Neuron 2 ProteinnusinersenOligonucleotidesRNA, MessengerSMN2 protein, mouseSurvival of Motor Neuron 2 Protein

Identifiers

PMID32612161
PMCPMC7330045
OpenAlexW3039651163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.